These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 8958782

  • 1. Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma.
    Wassberg E, Stridsberg M, Christofferson R.
    J Endocrinol; 1996 Nov; 151(2):225-30. PubMed ID: 8958782
    [Abstract] [Full Text] [Related]

  • 2. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
    Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, Bidart JM, Cailleux AF, Bonacci R, Ruffié P, Schlumberger M.
    Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
    [Abstract] [Full Text] [Related]

  • 3. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma.
    Stridsberg M, Husebye ES.
    Eur J Endocrinol; 1997 Jan; 136(1):67-73. PubMed ID: 9037129
    [Abstract] [Full Text] [Related]

  • 4. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
    Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL.
    Prostate; 1997 Jan 01; 30(1):1-6. PubMed ID: 9018329
    [Abstract] [Full Text] [Related]

  • 5. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.
    Georgantzi K, Sköldenberg EG, Stridsberg M, Kogner P, Jakobson Å, Janson ET, Christofferson RHB.
    Pediatr Hematol Oncol; 2018 Mar 01; 35(2):156-165. PubMed ID: 29737901
    [Abstract] [Full Text] [Related]

  • 6. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.
    Stridsberg M, Oberg K, Li Q, Engström U, Lundqvist G.
    J Endocrinol; 1995 Jan 01; 144(1):49-59. PubMed ID: 7891024
    [Abstract] [Full Text] [Related]

  • 7. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E.
    Ann Oncol; 2001 Jan 01; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [Abstract] [Full Text] [Related]

  • 8. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
    Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SW.
    J Clin Endocrinol Metab; 1997 Aug 01; 82(8):2622-8. PubMed ID: 9253344
    [Abstract] [Full Text] [Related]

  • 9. Tumour markers are poor predictors for relapse or progression in neuroblastoma.
    Simon T, Hero B, Hunneman DH, Berthold F.
    Eur J Cancer; 2003 Sep 01; 39(13):1899-903. PubMed ID: 12932669
    [Abstract] [Full Text] [Related]

  • 10. Pancreastatin immunoreactivity in favourable childhood neuroblastoma and ganglioneuroma.
    Kogner P, Bjellerup P, Svensson T, Theodorsson E.
    Eur J Cancer; 1995 Sep 01; 31A(4):557-60. PubMed ID: 7576967
    [Abstract] [Full Text] [Related]

  • 11. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
    Hvamstad T, Jordal A, Hekmat N, Paus E, Fosså SD.
    Eur Urol; 2003 Aug 01; 44(2):215-21. PubMed ID: 12875941
    [Abstract] [Full Text] [Related]

  • 12. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes.
    De Block CE, Colpin G, Thielemans K, Coopmans W, Bogers JJ, Pelckmans PA, Van Marck EA, Van Hoof V, Martin M, De Leeuw IH, Bouillon R, Van Gaal LF.
    Diabetes Care; 2004 Jun 01; 27(6):1387-93. PubMed ID: 15161793
    [Abstract] [Full Text] [Related]

  • 13. Circulating neuroendocrine markers in patients with prostate carcinoma.
    Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, Tarabuzzi R, Bollito E, Fontana D, Angeli A.
    Cancer; 2000 Jun 01; 88(11):2590-7. PubMed ID: 10861438
    [Abstract] [Full Text] [Related]

  • 14. Serum chromogranin-A in advanced prostate cancer.
    Ferrero-Poüs M, Hersant AM, Pecking A, Brésard-Leroy M, Pichon MF.
    BJU Int; 2001 Nov 01; 88(7):790-6. PubMed ID: 11890255
    [Abstract] [Full Text] [Related]

  • 15. Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer: comparative evaluation with neuron-specific enolase.
    Giovanella L, Ceriani L, Bandera M, Garancini S.
    Int J Biol Markers; 2001 Nov 01; 16(1):50-5. PubMed ID: 11288956
    [Abstract] [Full Text] [Related]

  • 16. Comparison of chromogranin A and pancreastatin levels in plasma of patients with pancreatic islet cell tumor.
    Tateishi K, Kitayama N, Matsuoka Y, Funakoshi A.
    Life Sci; 1995 Nov 01; 57(9):889-95. PubMed ID: 7630318
    [Abstract] [Full Text] [Related]

  • 17. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
    Fan L, Wang Y, Chi C, Pan J, Xun S, Xin Z, Hu J, Zhou L, Dong B, Xue W.
    BJU Int; 2017 Aug 01; 120(2):226-232. PubMed ID: 28107595
    [Abstract] [Full Text] [Related]

  • 18. High plasma levels of human chromogranin A and adrenomedullin in patients with pheochromocytoma.
    Cotesta D, Caliumi C, Alò P, Petramala L, Reale MG, Masciangelo R, Signore A, Cianci R, D'Erasmo E, Letizia C.
    Tumori; 2005 Aug 01; 91(1):53-8. PubMed ID: 15850005
    [Abstract] [Full Text] [Related]

  • 19. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
    Nisman B, Heching N, Biran H, Barak V, Peretz T.
    Tumour Biol; 2006 Aug 01; 27(1):8-16. PubMed ID: 16340245
    [Abstract] [Full Text] [Related]

  • 20. Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival.
    Hsiao RJ, Seeger RC, Yu AL, O'Connor DT.
    J Clin Invest; 1990 May 01; 85(5):1555-9. PubMed ID: 2332506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.